David Lebowitz
Stock Analyst at Citigroup
(3.27)
# 1,005
Out of 4,876 analysts
113
Total ratings
50%
Success rate
1.61%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Upgrades: Neutral | $83 → $129 | $128.11 | +0.69% | 6 | Jun 4, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $43.67 | +28.23% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $9.56 | +4.60% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $33.16 | +141.25% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.25 | +20.00% | 6 | Mar 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $44.86 | +9.23% | 4 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $39.80 | +60.80% | 12 | Feb 20, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $49.84 | -9.71% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $68.37 | +28.71% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $26.52 | +43.29% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $51.07 | +33.15% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $20.28 | +245.17% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.10 | +111.27% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $172.14 | +20.25% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $20.61 | +79.52% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $300.75 | +27.02% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $55.17 | +74.01% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $3.53 | +239.94% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $322.83 | -49.20% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.74 | +183.84% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $9.03 | +132.69% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.33 | +9,253.35% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.73 | +1,815.45% | 2 | Oct 12, 2021 |
Blueprint Medicines
Jun 4, 2025
Upgrades: Neutral
Price Target: $83 → $129
Current: $128.11
Upside: +0.69%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $43.67
Upside: +28.23%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.56
Upside: +4.60%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $33.16
Upside: +141.25%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.25
Upside: +20.00%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $44.86
Upside: +9.23%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $39.80
Upside: +60.80%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $49.84
Upside: -9.71%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $68.37
Upside: +28.71%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $26.52
Upside: +43.29%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $51.07
Upside: +33.15%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $20.28
Upside: +245.17%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.10
Upside: +111.27%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $172.14
Upside: +20.25%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $20.61
Upside: +79.52%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $300.75
Upside: +27.02%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $55.17
Upside: +74.01%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $3.53
Upside: +239.94%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $322.83
Upside: -49.20%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.74
Upside: +183.84%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $9.03
Upside: +132.69%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.33
Upside: +9,253.35%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.73
Upside: +1,815.45%